Carrier Free, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Inotuzumab (anti-CD22) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab (anti-CD22) can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab (anti-CD22) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Inotuzumab (anti-CD22) (Ab176429) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD22 with Inotuzumab (anti-CD22) (Ab176429) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156150).
Inotuzumab (anti-CD22) (Ab176429) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD22 (red) with Inotuzumab (anti-CD22) (Ab176429) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Inotuzumab (anti-CD22) (Ab176429) - Flow Cytometry
Flow Cytometry analysis of Ramos cells labelling CD22 (red) with Inotuzumab (anti-CD22) (Ab176429). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Inotuzumab (anti-CD22) (Ab176429) - SEC
The purity of Inotuzumab (anti-CD22) (Ab176429) is more than 95% verified by HPLC.
Inotuzumab (anti-CD22) (Ab176429) - ELISA
Immobilized Recombinant Human Siglec-2/CD22 Protein (rp169575) at 1.0 μg/mL can bind Inotuzumab (anti-CD22) (Ab176429) with the EC₅₀ of 20.07 ng/mL.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001500 | Certificate of Analysis | Nov 02, 2023 | Ab176429 |
| ZJ23F1001499 | Certificate of Analysis | Nov 02, 2023 | Ab176429 |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
